Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biological material for composite fibroblast growth factor 1 and application of biological material in preparation of medicines for treating lower limb ischemia

A fibroblast and growth factor technology, applied in cardiovascular system diseases, medical preparations containing active ingredients, drug combinations, etc., can solve problems such as high cost, achieve easy acceptance, promote functional recovery, and improve motor function.

Inactive Publication Date: 2015-02-04
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, conservative medical therapy and surgical traumatic treatment are usually used for lower extremity arterial ischemic diseases, but they can only alleviate and alleviate the symptoms and progress of the disease, and the cost of surgical traumatic treatment is relatively expensive. Relatively cheap universal treatment to help patients restore lower limb motor function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological material for composite fibroblast growth factor 1 and application of biological material in preparation of medicines for treating lower limb ischemia
  • Biological material for composite fibroblast growth factor 1 and application of biological material in preparation of medicines for treating lower limb ischemia
  • Biological material for composite fibroblast growth factor 1 and application of biological material in preparation of medicines for treating lower limb ischemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1: Synthesis of RAD16-II polypeptide

[0028] 1. Materials and equipment

[0029] 1.1 Reagents

[0030] Fluorenylmethoxycarbonyl (Fmoc)-amino acid is a product of SIAM in the United States; PyBOP, Boc-Ala-Merrifield resin, hexahydropyridine, and lutidine are products of Merck; dimethylformamide (DMF) is a product of Samsung, Japan Products (soaked in ninhydrin and Molecular sieve dehydration, and determination of no free amino groups); dichloromethane (DCM) is a product of China Pharmaceutical (Group) Shanghai Chemical Reagent Company (soaked with anhydrous potassium carbonate before use); trifluoroacetic acid (TFA) is a product of GEEL BELGIUM company Methanol is a product of Shanghai Zhenxing Chemical Factory No. 1; HPLC methanol is a product of Merck; tetrahydrofuran is a product of Shanghai Chemical Reagent Station Central Chemical Factory.

[0031] 1.2 Instruments

[0032] The 431A peptide synthesizer is the product of Applied biosystems; the high p...

Embodiment 2

[0060] Embodiment 2: the preparation of the biological material of composite fibroblast growth factor 1 (FGF1)

[0061] 1. Reagents and equipment

[0062] 1.1 Reagents: RAD16-II polypeptide prepared in Example 1; FGF1 purchased from R&D Company; sucrose solution.

[0063] 1.2 Instruments: ultra-clean table; ultrasonic instrument; 4 ℃ refrigerator.

[0064] 2. Preparation method

[0065] (1) Sterilization of deionized water

[0066] Take 500ml of deionized water (18MΩ) in the pure water system (Millipore Milli-Q system), and use the standard process of autoclaving to sterilize, that is, treat the deionized water at a vapor pressure of 103.4kPa and a temperature of 121.3°C for 30 Minutes, and then sterilized deionized water was sealed and stored in a refrigerator at 4°C for later use;

[0067] (2) Prepare sucrose sterile solution

[0068] At room temperature and normal pressure, the sucrose was prepared into a sucrose solution with a concentration of 100 mg / mL with the deio...

Embodiment 3

[0073] Embodiment 3: the preparation of the biological material of composite fibroblast growth factor 1 (FGF1)

[0074] 1. Reagents and equipment

[0075] 1.1 Reagents: RAD16-II polypeptide prepared in Example 1; FGF1 purchased from R&D Company; sucrose solution.

[0076] 1.2 Instruments: ultra-clean table; ultrasonic instrument; 4 ℃ refrigerator.

[0077] 2. Preparation method

[0078] (1) Sterilization of deionized water

[0079] Same as the sterilization treatment of deionized water in Example 2.

[0080] (2) Prepare sucrose sterile solution

[0081] With the preparation of sucrose solution among the embodiment 2.

[0082] (3) Preparation of raw material solution

[0083] Dissolve the RAD16-II polypeptide and FGF1 prepared in the embodiment in the aseptic environment of the ultra-clean bench at room temperature and normal pressure in the sucrose solution sterilized in step (2) to form a mixed solution. In the mixed solution, RAD16 The concentration of -II polypeptide...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a biological material for a composite fibroblast growth factor 1. The biological material is formed by mixing a polypeptide RAD16-II, a fibroblast growth factor 1 and a solvent capable of dissolving the polypeptide RAD16-II and the fibroblast growth factor 1, wherein the amino acid sequence of the polypeptide RAD16-II is shown as SEQ ID NO:1 in a sequence table, or the polypeptide RAD16-II is a polypeptide with at least 60 percent of homology with the amino acid sequence shown as SEQ ID NO:1. A lower limb ischemia animal model is subjected to intervention treatment by using the biological material for the composite fibroblast growth factor 1, so that the movement functions of ischemic lower limbs of animals can be obviously improved, and the biological material disclosed by the invention can be applied to preparing medicines for treating the lower limb ischemia.

Description

technical field [0001] The invention belongs to the field of biomaterials, in particular to a biomaterial compounded with fibroblast growth factor 1 and its application in the preparation of medicines for treating ischemic diseases of lower limbs. Background technique [0002] Lower extremity ischemic disease is a common peripheral vascular disease caused by chronic stenosis or occlusion of lower extremity arteries, and its incidence is increasing rapidly year by year. According to statistics, the latest incidence of critical limb ischemia (CLI) in western countries is 500-1000 / million people / year, and the number of cases in the United States is 150,000-300,000 per year. The first-year morbidity and mortality of CLI exceeds that of malignancy, with an amputation rate of 30% and a mortality rate of 25%. There are more than 20 million lower limb ischemia patients in my country, and the annual increase is as high as 600,000. Ischemic diseases of the lower extremities are ofte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61K47/42A61P9/10
Inventor 唐成康
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com